Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5490823 | 0.99 | SRC (0.55) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL6210593 | 0.92 | SRC (0.54) | SRCEGFRERBB2 | |
| SCHEMBL4487359 | 0.88 | SRC (0.57) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4498795 | 0.88 | SRC (0.63) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4495250 | 0.85 | SRC (0.60) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL5452058 | 0.84 | SRC (0.55) | SRCEGFRERBB2ABL1BCR | |
| Hydrochloric Acid SCHEMBL5466160 | 0.84 | SRC (0.55) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL5464328 | 0.82 | SRC (0.54) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4498460 | 0.81 | SRC (0.66) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL5460734 | 0.81 | SRC (0.56) | SRCEGFRERBB2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | claimed |
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | SRC 147/4885EGFR 241/4885ERBB2 168/4885 |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | MAPK1, MAPK3, MAPK4 | SRC 49/4885EGFR 80/4885ERBB2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.